fam-trastuzumab deruxtecan
Selected indexed studies
- The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. (Chem Pharm Bull (Tokyo), 2019) [PMID:30827997]
- A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer. (Ann Pharmacother, 2021) [PMID:33629601]
- Trastuzumab Deruxtecan. (, 2006) [PMID:33226745]
_Worker-drafted node — pending editorial review._
Connections
fam-trastuzumab deruxtecan is a side effect of
Sources
- Trastuzumab Deruxtecan. (2006) pubmed
- The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. (2019) pubmed
- A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer. (2021) pubmed
- Trastuzumab Deruxtecan. (2012) pubmed
- Fam-Trastuzumab Deruxtecan (Enhertu) Induced Pyloric Perforation in Hormone Receptor-positive/HER2-low Expresses Metastatic Breast Cancer. (2023) pubmed
- Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer. (2023) pubmed
- FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. (2024) pubmed
- The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. (2023) pubmed
- Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. (2022) pubmed
- Enhertu (Fam-trastuzumab-deruxtecan-nxki) - Revolutionizing treatment paradigm for HER2-Low breast cancer. (2022) pubmed